Approach to the treatment of newly diagnosed myeloma in patients eligible for transplantation (A) and not eligible for transplantation (B). *For patients who choose delayed ASCT, dexamethasone usually discontinued after 12 months and continued long-term lenalidomide is an option for patients who are tolerating treatment well. Modified with permission from Rajkumar.²